Few safe havens surface in another down quarter for biopharma

Three quarters of the trading year are done, and many biopharma stocks are in a perilous state. With big pharma now feeling the pressure alongside small and mid-cap groups, safe havens are proving hard to find.

The unwinding of the Covid trade is readily apparent in Evaluate Vantage’s latest quarterly look at the sector’s biggest winners and losers. And on the up are developers that have delivered pipeline progress, like Lilly, Daiichi and Sarepta.

This analysis was constructed from the almost 700 listed biopharma companies covered by Evaluate Pharma, and that were worth at least $250m at the start of 2022. These stocks, sorted into four cohorts based on year-end 2021 valuations, are being tracked by Evaluate Vantage over the year.